Eventide Asset Management, LLC Celldex Therapeutics, Inc. Transaction History

Eventide Asset Management, LLC

$4.71 Billion
Q1 2025

A detailed history of Eventide Asset Management, LLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Eventide Asset Management, LLC holds 3,754,793 shares of CLDX stock, worth $73.3 Million. This represents 1.45% of its overall portfolio holdings.

Number of Shares

3,754,793

Previous 3,753,260 0.04%

Holding current value

$73.3 Million

Previous $94.8 Million 28.15%

% of portfolio

1.45%

Previous 1.82%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$18.15 - $27.6 $27,823 - $42,310	1,533 Added 0.04%	3,754,793 $68.1 Million
Q4 2024 Feb 14, 2025	BUY	$23.31 - $32.4 $9.82 Million - $13.6 Million	421,255 Added 12.64%	3,753,260 $94.8 Million
Q3 2024 Nov 14, 2024	BUY	$32.06 - $44.56 $156,228 - $217,140	4,873 Added 0.15%	3,332,005 $113 Million
Q2 2024 Aug 13, 2024	BUY	$32.76 - $42.56 $6.82 Million - $8.85 Million	208,045 Added 6.67%	3,327,132 $123 Million
Q1 2024 May 15, 2024	SELL	$35.22 - $51.88 $18 Million - $26.5 Million	-510,926 Reduced 14.08%	3,119,087 $131 Million
Q4 2023 Feb 14, 2024	BUY	$22.61 - $40.65 $45.9 Million - $82.5 Million	2,030,013 Added 126.88%	3,630,013 $144 Million
Q3 2023 Nov 14, 2023	BUY	$25.45 - $37.46 $5.66 Million - $8.33 Million	222,260 Added 16.13%	1,600,000 $44 Million
Q1 2023 May 15, 2023	SELL	$34.78 - $47.43 $2.97 Million - $4.05 Million	-85,310 Reduced 5.83%	1,377,740 $49.6 Million
Q4 2022 Feb 13, 2023	SELL	$27.78 - $45.38 $9.13 Million - $14.9 Million	-328,750 Reduced 18.35%	1,463,050 $65.2 Million
Q3 2022 Nov 14, 2022	BUY	$22.7 - $37.57 $7.86 Million - $13 Million	346,100 Added 23.94%	1,791,800 $50.4 Million
Q1 2022 May 16, 2022	BUY	$27.64 - $39.32 $5.72 Million - $8.13 Million	206,800 Added 16.69%	1,445,700 $49.2 Million
Q4 2021 Feb 14, 2022	BUY	$35.68 - $56.27 $3.96 Million - $6.24 Million	110,900 Added 9.83%	1,238,900 $47.9 Million
Q3 2021 Nov 15, 2021	SELL	$28.95 - $55.99 $28.4 Million - $54.9 Million	-980,908 Reduced 46.51%	1,128,000 $60.9 Million
Q2 2021 Aug 16, 2021	BUY	$20.71 - $35.37 $962,497 - $1.64 Million	46,475 Added 2.25%	2,108,908 $70.5 Million
Q1 2021 May 14, 2021	BUY	$16.19 - $29.91 $3.65 Million - $6.74 Million	225,325 Added 12.27%	2,062,433 $42.5 Million
Q4 2020 Feb 16, 2021	BUY	$14.99 - $22.75 $20 Million - $30.3 Million	1,330,929 Added 262.94%	1,837,108 $32.2 Million
Q3 2020 Nov 13, 2020	BUY	$9.65 - $15.19 $413,444 - $650,800	42,844 Added 9.25%	506,179 $7.51 Million
Q2 2020 Aug 14, 2020	BUY	$1.61 - $13.41 $745,969 - $6.21 Million	463,335 New	463,335 $6.02 Million

Others Institutions Holding CLDX

# of Institutions

188

Shares Held

69.3M

Call Options Held

220K

Put Options Held

310K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $913M
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eventide Asset Management, LLC with notifications on news.

Account

Eventide Asset Management, LLC Celldex Therapeutics, Inc. Transaction History